Polymer Technology Systems, Inc.

pstPolymer Technology Systems, Inc. (PTS) is a US-based manufacturer of advanced point-of-care (POC) diagnostic systems, specializing in rapid testing solutions for chronic diseases such as cardiovascular disease, diabetes, and metabolic disorders. With a focus on portable, accurate, and cost-effective diagnostic tools, PTS provides healthcare professionals and patients with immediate, actionable health data, eliminating the delays and expenses associated with traditional laboratory testing. The company’s flagship products – CardioChek® PA and A1CNow+ – have become essential tools in managing cholesterol, glucose, and HbA1c levels, supporting early diagnosis, risk assessment, and ongoing treatment monitoring for millions of patients worldwide.

CardioChek® PA – Rapid Lipid and Metabolic Testing in One Portable Device

The CardioChek® PA analyzer is a compact, highly precise spectrophotometric system designed for rapid lipid and metabolic profile testing using capillary whole blood samples. This device provides clinicians, pharmacies, and home users with an efficient and cost-effective alternative to lab-based lipid testing, delivering results in just two minutes.

Comprehensive Lipid and Metabolic Panel Capabilities

CardioChek® PA can measure a wide range of key biomarkers, essential for assessing cardiovascular and metabolic health:

  • Total Cholesterol – Evaluates overall cholesterol levels and helps assess the risk of heart disease.
  • HDL Cholesterol – High-density lipoprotein (HDL) is crucial for cardiovascular health, often referred to as “good cholesterol.”
  • LDL Cholesterol (Direct Measurement) – The primary risk factor for atherosclerosis and cardiovascular disease, CardioChek® PA provides direct LDL measurements for more accurate risk assessment.
  • Triglycerides – High levels are associated with increased heart disease and diabetes risk.
  • Glucose – A critical parameter for diabetes screening and monitoring, allowing for quick blood sugar evaluations.
  • Ketones – Useful for diabetic ketoacidosis (DKA) monitoring and metabolic health assessments.
  • Creatinine – A key marker of kidney function, especially important for patients with diabetes or hypertension.

With single-use test strips, the CardioChek® PA eliminates the need for complex lab processing, making it an ideal solution for primary care clinics, pharmacies, wellness programs, and remote healthcare facilities.

Advantages of CardioChek® PA in Routine Care

  • Portable and easy to use, requiring minimal training.
  • Lab-quality results in just 2 minutes, supporting on-the-spot decision-making.
  • Capillary whole blood sample compatibility, reducing patient discomfort and invasive procedures.
  • Flexible testing panels, allowing for customized lipid and metabolic screenings.
  • Cost-effective alternative to lab-based lipid panels, improving access to cardiovascular risk assessment in resource-limited settings.

CardioChek® PA is currently available in Mexico, Colombia, and Brazil, making high-quality lipid testing accessible across key Latin American markets where cardiovascular disease remains the leading cause of mortality.

A1CNow+: Immediate HbA1c Results for Diabetes Management

Managing diabetes effectively requires long-term blood sugar control, which is best assessed through HbA1c testing. The A1CNow+ analyzer fills a critical gap in diabetes care, providing fast, reliable HbA1c measurements in primary care clinics, pharmacies, and at the point of care.

Why HbA1c Testing Matters

Unlike daily glucose testing, which reflects immediate blood sugar levels, HbA1c provides an average glucose reading over the past 2–3 months. This measurement is crucial for:

  • Diagnosing prediabetes and diabetes.
  • Assessing treatment effectiveness and medication adjustments.
  • Identifying patients at risk for diabetes-related complications.

How A1CNow+ Transforms Diabetes Monitoring

Traditional HbA1c testing requires venous blood draws and laboratory processing, which can be costly and time-consuming. The A1CNow+ analyzer offers a simpler, more efficient alternative, allowing clinicians and pharmacists to provide immediate HbA1c results without relying on centralized labs.

Key features include:

  • On-the-spot results within 5 minutes, eliminating the need for lab referrals.
  • Requires only a small capillary blood sample, making it less invasive than traditional lab testing.
  • Portable and easy to use, suitable for in-office or community health screenings.
  • Reduces patient follow-up delays, allowing for immediate treatment plan adjustments.

By removing the barriers of cost, processing time, and complexity, A1CNow+ enables more frequent testing, ensuring that patients receive real-time feedback on their diabetes control.

Why These Technologies Matter for Healthcare in Mexico and the US

In both Mexico and the US, chronic diseases like cardiovascular disease and diabetes are leading causes of death. According to the CDC, over 37 million people in the US have diabetes, while in Mexico, 14% of the adult population is affected by the disease. Similarly, heart disease remains the #1 cause of death in both countries, making accessible lipid and metabolic testing a healthcare priority.

The CardioChek® PA and A1CNow+ analyzers address key challenges in chronic disease management by:

  • Reducing diagnostic wait times, allowing for faster medical intervention.
  • Making lipid and HbA1c testing available outside of hospital settings, improving access to essential diagnostics.
  • Lowering costs compared to lab-based testing, particularly in underserved and rural areas.
  • Enhancing preventive healthcare efforts, allowing early detection of cardiovascular risk factors and diabetes.